Rocket Pharmaceuticals appoints Christopher Stevens as COO; Patel shifts to President, Head of R&D

ROCKET PHARMACEUTICALS, INC.

Christopher Stevens, age 45, appointed COO effective July 7, 2025; previously EVP at Spark Therapeutics.
Kinnari Patel transitions from COO, President, Head of R&D to President, Head of R&D.
Stevens receives $525,000 base salary, 45% target bonus, $250,000 sign-on, and ~$2.5M equity grant.
Equity vests over 3 years; additional $500K equity grant after one year.
Severance provisions: 9 months base plus COBRA; 12 months on change-in-control termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.